A translational approach to micro-inflammation in end-stage renal disease: Molecular effects of low levels of interleukin-6

Clinical Science

Volumn 119, Issue 4, 2010, Pages 163-174

  Memoli, Bruno ^a   Salerno, Simona ^b   Procino, Alfredo ^a   Postiglione, Loredana ^a   Morelli, Sabrina ^b   Sirico, Maria Luisa ^a   Giordano, Francesca ^b   Ricciardone, Margherita ^a   Drioli, Enrico ^b   Andreucci, Vittorio E ^a   De Bartolo, Loredana ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF CALABRIA   (Italy)

Author keywords

End stage renal disease (ESRD); Fetuin A; Hepcidin; Interleukin 6 (IL 6); Micro inflammation; Signal transducer and activator of transcription 3 (STAT3)

Indexed keywords

FETUIN A; HEPCIDIN; INTERLEUKIN 6; PROTEIN; RECOMBINANT INTERLEUKIN 6; STAT3 PROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CELL CULTURE; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; KIDNEY FAILURE; LIVER CELL; MALE; MORTALITY; PRIORITY JOURNAL; SERUM; UPREGULATION; WESTERN BLOTTING;

ADULT; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD PROTEINS; C-REACTIVE PROTEIN; CELLS, CULTURED; CYTOKINE RECEPTOR GP130; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; RECOMBINANT PROTEINS; RENAL DIALYSIS; STAT3 TRANSCRIPTION FACTOR;

EID: 77954914474     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20090634     Document Type: Article

References (45)

1. Schiffrin, E. L., Lipman, M. L. and Mann, F. E. (2007) Chronic kidney disease: effects on the cardiovascular system. Circulation 116, 85-97 (Pubitemid 47016250)
2. Kaysen, G. A. (2001) The microinflammatory state in uremia: causes and potential consequences. J. Am. Soc. Nephrol. 12, 1549-1557
3. Cozzolino, M., Brancaccio, D., Gallieni, M. and Slatopolsky, E. (2005) Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int. 68, 429-436 (Pubitemid 43323098)
4. Levin, A. (2002) Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int. 61, (Suppl. 80), S35-S38
5. Memoli, B., Libetta, C., Rampino, T., Dal Canton, A., Conte, G., Scala, G., Ruocco, M. R. and Andreucci, V. E. (1992) Hemodialysis related induction of interleukin 6 production by peripheral blood mononuclear cells. Kidney Int. 42, 320-326
6. Memoli, B., Minutolo, R., Bisesti, V., Postiglione, L., Conti, A., Marzano, L., Capuano, A., Andreucci, M., Balletta, M. M., Guida, B. and Tetta, C. (2002) Changes of serum albumin and C-reactive protein are related to changes of interleukin 6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am. J. Kidney Dis. 39, 266-273
7. Stenvinkel, P., Barany, P., Heimburger, O., Pecoits-Filho, R. and Lindholm, B. (2002) Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin 6? Kidney Int. 61, (Suppl. 80), S103-S108
8. Bologa, R. M., Levine, D. M., Parker, T. S., Cheigh, J. S., Serur, D., Stenzel, K. H. and Rubin, A. L. (1998) Interleukin 6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am. J. Kidney Dis. 32, 107-114
9. Yeun, J. Y., Levine, R. A., Mantadilok, V. and Kaysen, G. A. (2000) C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 35, 469-476
10. Rao, M., Guo, D., Perianayagam, M. C., Tighiouart, H., Jaber, B. L., Pereira, B. J. and Balakrishnan, V. S. (2005) Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 45, 324-333
11. Knupfer, H. and Preiss, R. (2008) sIL-6R: more than an agonist? Immunol. Cell Biol. 86, 87-91
12. Heinrich, P. C., Graeve, L., Rose-John, S., Schneider-Mergener, J., Dittrich, E., Erren, A., Gerhartz, C., Hemmann, U., Lutticken, C., Wegenka, U. et al. (1995) Membrane-bound and soluble interleukin 6 receptor: studies on structure, regulation of expression and signal transduction. Ann. N.Y. Acad. Sci. 762, 222-236
13. Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F. and Graeve, L. (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334, 297-314 (Pubitemid 28448572)
14. Levy, D. E. and Lee, C. K. (2002) What does Stat3 do? J. Clin. Invest. 109, 1143-1148
15. Ketteler, M., Bongartz, P.,Westenfeld, R.,Wildberger, J. E., Mahnken, A. H., Bohm, R., Metzger, T.,Wanner, C., Jahnen-Dechent, W. and Floege, J. (2003) Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361, 827-833
16. Ashby, D. R., Gale, D. P., Busbridge, M., Murphy, K. G., Duncan, N. D., Cairns, T. D., Taube, D. H., Bloom, S. R., Tam, F. W., Chapman, R. S. et al. (2009) Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 75, 976-981
17. Schafer, C., Heiss, A., Schwarz, A., Westenfeld, R., Ketteler, M., Floege, J., Muller-Esterl, W., Schinke, T. and Jahnen-Dechent, W. (2003) The serum protein α2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J. Clin. Invest. 112, 357-366
18. Memoli, B., De Bartolo, L., Favia, P., Morelli, S., Lopez, L. C., Procino, A., Barbieri, G., Curcio, E., Giorno, L., Esposito, P. et al. (2007) Fetuin-A gene expression, synthesis and release in primary human hepatocytes cultured in a galactosylated membrane bioreactor. Biomaterials 28, 4836-4844
19. Ganz, T. (2007) Molecular control of iron transport. J. Am. Soc. Nephrol. 18, 394-400
20. Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A. and Ganz, T. (2003) Hepcidin, a putative mediator of inflammation, is a type II acute phase protein. Blood 101, 2461-2463 (Pubitemid 36857598)
21. Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K. and Ganz, T. (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113, 1271-1276
22. Wrighting, D. M. and Andrews, N. C. (2006) Interleukin 6 induces hepcidin expression through STAT3. Blood 108, 3204-3209
23. Zalunardo, N. and Levin, A. (2006) Anemia and the hearth in chronic kidney disease. Semin. Nephrol. 26, 290-295
24. Yildiz, A., Oflaz, H., Pusuroglu, H., Mercanoglu, F., Genchallac, H., Akkaya, V., Iklizer, T. A. and Sever, M. S. (2003) Left ventricular hypertrophy and endothelial dysfunction in chronic hemodialysis patients. Am. J. Kidney Dis. 41, 616-623
25. Tsirpanlis, G., Bagos, P., Ioannou, D., Bleta, A., Marinou, I., Lagouranis, A., Chatzipanagiotou, S. and Nicolaou, C. (2004) The variability and accurate assessment of microinflammation in hemodialysis patients. Nephrol. Dial. Transplant. 19, 150-157
26. Liu, Y., Coresh, J., Eustace, J. A., Longenecker, J. C., Jaar, B., Fink,N. E., Tracy, R. P., Power,N. R. and Klag, M. J. (2004) Association between cholesterol level and mortality in dialysis patients. JAMA, J. Am. Med. Assoc. 291, 451-459
27. Preti, H. A., Cabanillas, F., Talpaz, M., Tucker, S. L., Seymour, J. F. and Kurzrock, R. (1997) Prognostic value of serum interleukin 6 in diffuse large cell lymphoma. Ann. Intern. Med. 127, 186-194
28. Ridker, P. M., Rifai, N., Stampfer, M. J. and Hennekens, C. H. (2000) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101, 1767-1772 (Pubitemid 30213096)
29. Memoli, B. Salerno, S. Procino, A., Postiglione, L., Morelli, S., Sirico, M. L., Drioli, E., Andreucci, V. E. and De Bartolo, L. (2008) IL-6 from ESRD patients is sufficient to activate STAT3 and regulate gene expression of hepcidin and fetuin-A in human hepatocytes. J. Am. Soc. Nephrol. 19, 265A
30. Pearson, T. A., Mensah, G. A., Wayne, A. R., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L. et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice. Circulation 107, 499-511
31. De Bartolo, L., Morelli, S., Rende, M., Gordano, A. and Drioli, E. (2004) New modified polyetheretherketone membrane for liver cell culture in biohybrid systems: adhesion and specific functions of isolated hepatocytes. Biomaterials 25, 3621-3629 (Pubitemid 38327050)
32. Panno, M. L., Giordano, F., Mastroianni, F., Morelli, C., Brunelli, E., Palma, M. G., Pellegrino, M., Aquila, S., Miglietta, A., Mauro, L. et al. (2006) Evidence that low doses of Taxol enhance the functional transactivatory properties of p53 on p21 waf promoter in MCF-7 breast cancer cells. FEBS Lett. 580, 2371-2380
33. Memoli, B., Postiglione, L., Cianciaruso, B., Bisesti, V., Cimmaruta, C., Marzano, L., Minutolo, R., Cuomo, V., Guida, B., Andreucci, M. and Rossi, G. (2000) Role of different dialysis membranes in the release of interleukin 6 soluble receptor in uremic patients. Kidney Int. 58, 417-424
34. Memoli, B., Grandaliano, G., Soccio, M., Postiglione, L., Guida, B., Bisesti, V., Esposito, P., Procino, A., Marrone, D., Michael, A. et al. (2005) In vivo modulation of soluble "antagonist" IL-6 receptor synthesis and release in end stage renal disease. J. Am. Soc. Nephrol. 16, 1099-1107
35. Pietrangelo, A., Dierssen, U., Valli, L., Garuti, C., Rump, A., Corradini, E., Ernst, M., Klein, C. and Trautwein, C. (2007) STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 132, 294-300
36. Gangneux, C., Daveau, M., Hiron, M., Derambure, C., Papaconstantinou, J. and Salier, J. P. (2003) The inflammation-induced down-regulation of plasma fetuin-A (α2HS-Glycoprotein) in liver results from the loss of interaction between long C/EBP isoforms at two neighboring binding sites. Nucleic Acids Res. 31, 5957-5970
37. Wöltje, M., Tschöke, B., von Bülow, V., Westenfeld, R., Denecke, B., Gräber, S. and Jahnen-Dechent, W. (2006) CCAAT enhancer binding protein and hepatocyte nuclear factor 3 are necessary and sufficient to mediate dexamethasone-induced up-regulation of α2HS-glycoprotein/fetuin-A gene expression. J. Mol. Endocrinol. 36, 261-277
38. Calkhoven, C. F., Muller, C. and Leutz, A. (2000) Translational control of C/EBP-α and C/EBP-β isoform expression. Genes Dev. 14, 1920-1932
39. Mackey, S. L. and Darlington, G. J. (2004) CCAAT Enhancer-binding protein is required for interleukin-6 receptor signaling in newborn hepatocytes. J. Biol. Chem. 279, 16206-16213
40. Nerlov, C. (2007) The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol. 17, 318-324
41. Moshage, H. (1997) Cytokines and the hepatic acute phase response. J. Pathol. 181, 257-266
42. Kramer, F., Torzewski, J., Kamenz, J., Veit, K., Hombach, V., Dedio, J. and Ivashchneko, Y. (2008) Interleukin-1β stimulates acute phase response and C-reactive protein synthesis by inducing an NFκB- and C/EBPβ-dependent autocrine interleukin-6 loop. Mol. Immunol. 45, 2678-2689
43. Jones, S. A., Horiuchi, S., Topley, N., Yamamoto, N. and Fuller, G. M. (2001) The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 15, 43-58
44. Mehrotra, R. (2007) Emerging role for fetuin-A as contributor to morbidity and mortality in chronic kidney disease. Kidney Int. 72, 137-140
45. Pertosa, G., Simone, S., Ciccone, M., Porreca, S., Zaza, G., Dalfino, G., Memoli, B., Procino, A., Bonomini, M., Sirolli, V. et al. (2009) Serum fetuin a in hemodialysis: a link between derangement of calcium-phosphorus homeostasis and progression of atherosclerosis? Am. J. Kidney Dis. 53, 467-474